Effect of dietary intake on Fibroscan screening results for metabolic associated fatty liver disease in children

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400086444

Enrollment

Unknown

Registered

2024-07-02

Start date

2024-07-02

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MAFLD

Interventions

Fasting group:No

Non fasting group:No

Eligibility

Sex/Gender

All

Age

6 Years to 18 Years

Inclusion criteria

Inclusion criteria: (1)aged between 6-18 years (2) agree to sign the informed consent

Exclusion criteria

Exclusion criteria: (1) Lack of necessary demographic indicators, body measurement indicators, laboratory indicators, ect (2) Liver disease with other causes or secondary hepatic steatosis caused by drugs, such as tamoxifen, hormones, etc (3) Combined with other serious diseases that may affect the nutritional status of the body, such as malignant tumors, serious organic diseases of the heart, lungs, kidneys, ect.

Design outcomes

Primary

Measure	Time frame
Fibroscan;	—

Countries

China

Contacts

Public ContactLe Zhang

Wuxi Children’s Hospital

zhangle@jiangnan.edu.cn+86 159 6170 5553

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026